## RGNX: REGENXBIO Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.0% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($11.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. REGENXBIO updates Phase 1/2 data for Duchenne candidate**
- Source: MSN | 20260103T010931 | Bullish | Relevance: 100%
- REGENXBIO plans to present updated interim data from its Phase 1/2 AFFINITY DUCHENNEÂ® study of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy, at the PPMD Annual Conference. The presentation will include safety and one-year expression data for patients in Cohort 1 and initial safety data for Cohorts 2 and 3. RGX-202 aims to deliver a novel microdystrophin transgene to muscle cells, potentially providing long-term benefits with a one-time treatment.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Stifel | $45 | $40 | +12% |
| 2025-12-15 | Leerink Partner | $20 | $16 | +25% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Stifel | main | Buy |
| 2025-12-15 | Leerink Partner | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.26M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.0% (+109.6%)
- Blackrock Inc.: 12.6% (-5.7%)
- Redmile Group, LLC: 9.3% (-1.7%)
- Vanguard Group Inc: 6.6% (-2.4%)
- State Street Corpora: 3.9% (+7.7%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.1% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (12.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.26 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.7x). Revenue growth strong at 35% YoY. Analyst sentiment positive (2 raises, avg +19%, $34 target (+154%)). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.7B |
| Beta | 1.07 |
| 52W Range | $5.04 - $15.41 |
| Short Interest | 12.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.26 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 5.1% to -3.0% (-8.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Underperforming sector by 3.5pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). RSI neutral at 49. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.97% (CS: 13) | Weak |
| RSI_14 | 49.1 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 0.972x | Below |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.357x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $13.40
- **Stop Loss:** $11.64 (13.1% risk)
- **Target:** $15.16 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 490
- **Position Value:** $6,566.00
- **Portfolio %:** 6.57%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-03-12 (Est: $-0.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.30 | $-1.20 | +7.6% |
| 2025Q2 | $-1.05 | $-1.38 | -30.8% |
| 2025Q1 | $0.49 | $0.12 | -75.3% |
| 2024Q4 | $-1.08 | $-1.01 | +6.9% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*